donanemab

all catalysts(0)

nothing on the calendar yet

News(5)

• Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
  With so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.
  biospace · 15d ago
• Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
  The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.
  biopharma_dive · 1mo ago
• STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more
  People on Medicare are not getting the recently approved Alzheimer’s medications nearly as much as federal officials anticipated
  stat · 3mo ago
• STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs
  Adoption has been slow with new Alzheimer’s drugs because the treatments are complicated to administer and the benefits are uncertain.
  stat · 3mo ago
• Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
  A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for both profit and revenue.
  biopharma_dive · 3mo ago